Jingruipin (Bosentan) 125mg*30's | China-Made Endothelin Receptor Antagonist | GLT

Generic Information: Jingruipin (China-Mainland)

Jingruipin is the domestic Chinese brand of bosentan, developed and manufactured by Beijing Sihuan Kebao Pharmaceutical Co., Ltd. It is the first generic bosentan approved in China and has passed the generic-drug consistency evaluation, confirming bioequivalence to the originator product. This listing covers the 125 mg strength in a 30-tablet box, the standard maintenance dose for adults with pulmonary arterial hypertension.

What Is Jingruipin Used For?

Jingruipin is used to treat pulmonary arterial hypertension (PAH), WHO functional class II to IV, to improve exercise ability and reduce clinical worsening. As a domestically manufactured alternative to the imported originator, it gives patients in China — and buyers sourcing from China — a locally produced option that meets national quality standards and lowers the cost of long-term therapy.

How Does Jingruipin (Bosentan) Work?

Jingruipin contains bosentan, a dual endothelin receptor antagonist that blocks both ETA and ETB receptors. By counteracting the elevated endothelin-1 that drives pulmonary blood-vessel constriction in PAH, it relaxes these vessels, lowers pulmonary vascular resistance, and reduces the workload on the right side of the heart. Because it has passed the consistency evaluation, Jingruipin delivers the same active ingredient and pharmacology as the originator.

Indications

Jingruipin is indicated for adults with pulmonary arterial hypertension (WHO Group 1), functional class II to IV. The medicine slows disease progression and improves exercise capacity. It is used as long-term, twice-daily therapy and is prescribed after the diagnosis of PAH is confirmed by a specialist.

Dosage

The standard adult regimen begins at 62.5 mg twice daily for the first four weeks, then increases to 125 mg twice daily. The 125 mg tablets in this listing are used for the maintenance phase. Take the tablets morning and evening, with or without food. Liver function must be checked before treatment and monthly, and women of childbearing potential must use reliable contraception because bosentan can cause birth defects.

Side Effects

Common side effects include headache, flushing, fluid retention, and abnormal liver function tests. Bosentan can also reduce hemoglobin, so blood counts are monitored. The most serious risks are liver toxicity and embryo-fetal toxicity, managed through monthly liver monitoring and strict contraception. Report any edema, weight gain, or worsening breathing problems promptly.

Storage

Store Jingruipin at room temperature, between 15°C and 30°C, in the original container, away from moisture, and out of the reach of children. No refrigeration is required.

Why Choose China-Sourced Jingruipin?

As the first domestically produced bosentan to pass the consistency evaluation, Jingruipin offers the same active ingredient as the originator at a more accessible price within China, and bosentan is covered by China's medical insurance. For buyers outside China, sourcing Jingruipin represents a lower-cost route to a quality-assured bosentan product compared with the originator's Western list price.

How to Order

To order Jingruipin through GLT, contact us on WhatsApp at +86 15234153837 or email [email protected]. Provide the strength, pack size, and destination country, and we will confirm sourcing, availability, and the export documents you need. We support both institutional purchasers and individual patients.

FAQ

Is Jingruipin a generic of bosentan? Yes. Jingruipin is the first domestically produced bosentan in China and has passed the generic-drug consistency evaluation, meaning it is bioequivalent to the originator.

Who makes Jingruipin? Jingruipin is manufactured by Beijing Sihuan Kebao Pharmaceutical Co., Ltd., a Chinese pharmaceutical company.

Is bosentan covered by insurance in China? Bosentan is included in China's national medical insurance drug list, which helps reduce the out-of-pocket cost for eligible patients.